In the latest trading session, 0.6 million PDS Biotechnology Corporation (NASDAQ:PDSB) shares changed hands as the company’s beta touched 1.66. With the company’s most recent per share price at $1.28 changed hands at -$0.06 or -4.10% at last look, the market valuation stands at $48.07M. PDSB’s current price is a discount, trading about -421.87% off its 52-week high of $6.68. The share price had its 52-week low at $1.25, which suggests the last value was 2.34% up since then.
Analysts gave the PDS Biotechnology Corporation (PDSB) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended PDSB as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. PDS Biotechnology Corporation’s EPS for the current quarter is expected to be -0.29.
PDS Biotechnology Corporation (NASDAQ:PDSB) trade information
Instantly PDSB was in red as seen in intraday trades today. With action -17.63%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -21.17%, with the 5-day performance at -17.63% in the red. However, in the 30-day time frame, PDS Biotechnology Corporation (NASDAQ:PDSB) is -14.90% down.
The consensus price target for the stock as assigned by Wall Street analysts is 9, meaning bulls need an upside of 85.78% from its recent market value. According to analyst projections, PDSB’s forecast low is 9 with 9 as the target high. To hit the forecast high, the stock’s price needs a -603.12% plunge from its current level, while the stock would need to soar -603.12% for it to hit the projected low.
PDS Biotechnology Corporation (PDSB) estimates and forecasts
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 42.97%. The 2025 estimates are for PDS Biotechnology Corporation earnings to increase by 12.41%, but the outlook for the next 5-year period is at 3.39% per year.
PDS Biotechnology Corporation (NASDAQ:PDSB)’s Major holders
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 1.3987% or 0.49 million shares worth $1.43 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. With 1.02 shares estimated at $1.3 million under it, the former controlled 2.72% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 1.22% of the shares, roughly 456.79 shares worth around $0.58 million.
